#United States #New Orleans #Orna Therapeutics #Autoimmune Diseases #CAR therapy

Orna Therapeutics to Present Groundbreaking CAR Therapy at ASGCT

Orna Therapeutics, a pioneering biotechnology enterprise focused on in vivo engineering of immune cells, has announced an exciting presentation at the upcoming 28th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. This prestigious event is scheduled to take place from May 13 to May 17, 2025, in the vibrant city of New Orleans, Louisiana. The focus of their presentation will revolve around the innovative in vivo CAR (Chimeric Antigen Receptor) therapy approach aimed at treating autoimmune diseases.

Joseph Bolen, Ph.D., the CEO of Orna Therapeutics, expressed the company’s anticipation for the presentation, stating, "We are excited to present new data at the upcoming ASGCT annual meeting as we advance our panCAR™ programs towards the clinic." This sentiment reflects a strong commitment to pushing the boundaries of gene therapy and autoimmune disease treatment.

The central theme of the presentation will spotlight the results from Orna’s panCAR™ therapy, which distinguishes itself through the utilization of circular RNA (oRNA®) technology. This innovative approach, accompanied by a leading lipid nanoparticle (LNP) delivery mechanism, opens up new avenues for drug development. One of the significant advantages of Orna’s platform is its ability to ensure sustained pharmacodynamic effects even at lower doses, which is critical for patients requiring long-term treatment. Moreover, durability in protein expression and the feasibility of repeat dosing make this therapy a potential game-changer in patient care for those suffering from autoimmune conditions.

Presentation Details

The presentation, titled "In Vivo panCAR™ Therapy Using Circular RNA for the Treatment of Autoimmune Disease," will be held on Thursday, May 15, 2025, from 8:00 AM to 9:45 AM CDT in Room 388-390. Leading the session will be Megan Hoban, Ph.D., who is at the forefront of the panCAR program within Orna Therapeutics.

As the industry gears up for this presentation, the data to be showcased is expected to demonstrate how Orna’s CD19 panCAR approach has resulted in deep and sustained depletion of B cells in non-human primate models, an essential feature when addressing B cell driven autoimmune diseases. This capability greatly expands the relevance of Orna’s innovations in real-world therapeutic scenarios.

About Orna Therapeutics

Orna Therapeutics is at the cutting edge of RNA medicine, focused on designing and delivering a next-generation therapeutic model based on circular RNA (oRNA®). This advanced approach not only simplifies production processes but also enhances formulations that integrate seamlessly into lipid nanoparticles, leading to superior protein expression outcomes compared to traditional mRNA therapies. Orna’s pioneering LNP delivery systems position the company uniquely in the biotechnology landscape, empowering the development of novel RNA medicines that hold significant promise for transforming patient care across various medical fields.

To delve deeper into Orna Therapeutics and their innovative solutions, visit www.ornatx.com and explore their presence on professional platforms like X and LinkedIn. With their ambitious goals and commitment to advancing health care, Orna Therapeutics is undeniably a company to watch in the evolving landscape of biotechnology.

Stay tuned for more updates as Orna Therapeutics continues on their path of innovation in gene therapy, with the future of autoimmune disease management hanging in the balance.